Mometasona Sandoz (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasona Sandoz, is a corticosteroid presented as an inhalation product for respiratory use. It reduces airway inflammation and hyper‑responsiveness in patients with asthma and chronic obstructive pulmonary disease.

GNH USA supplies Mometasona Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its manufacturing follows EU GMP guidelines, ensuring consistent potency and safety for patients across diverse markets.

Mometasone furoate inhalation acts on the respiratory tract to control chronic inflammatory airway diseases. - Asthma: improves control of symptoms and reduces frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation and helps maintain lung function.

Mometasone furoate inhalation may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Oral thrush: fungal infection of the mouth. - Hoarseness or dysphonia: voice changes due to laryngeal irritation. - Cough: transient irritation of the airway. - Throat irritation: soreness or dryness. - Headache: mild to moderate intensity. - Nasal irritation: mild congestion or dryness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pneumonia: infection of lung tissue. - Immunosuppression: increased susceptibility to infections. - Osteoporosis: decreased bone mineral density with long‑term use.

Before prescribing Mometasona Sandoz, clinicians should evaluate patient‑specific risk factors and ensure proper use. - Infection risk: assess for active respiratory infections before initiating therapy. - Growth monitoring: regularly check growth in pediatric patients receiving long‑term treatment. - Discontinuation: avoid abrupt cessation; taper the dose if therapy has been prolonged. - Inhaler technique: verify correct device handling to minimise local side effects. - Concomitant steroids: consider cumulative systemic corticosteroid exposure. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mometasone furoate inhalation can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Systemic corticosteroids: additive immunosuppressive effects. - Live vaccines: reduced vaccine efficacy and increased infection risk. - Ritonavir: potent CYP3A4 inhibition leading to higher steroid levels. - Antifungal azoles: heightened risk of adrenal suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug concentrations. - Diuretics: potential for electrolyte imbalance if systemic absorption occurs. - β2‑agonists: monitor for additive bronchodilator effects. - Antihistamines: watch for increased sedation. - Anticoagulants: possible alteration in bleeding risk.